Reacción a "Using beta blockers does not benefit patients who have survived a heart attack with normal cardiac function, according to a new study"

This meta-analysis uses rigorous methodology to analyse the results of five recent studies on treatment with beta-blockers in patients after acute myocardial infarction (AMI) with preserved ejection fraction.

It complements previous information and highlights the results of the REBOOT clinical trial. Beta-blockers do not provide any benefit in this specific group of patients, i.e., those with preserved ejection fraction after AMI. Unlike REBOOT, a new finding is that women do not experience adverse effects when analysing the five trials.

The message should be that beta-blockers should not be discontinued in all patients without consulting a specialist. The patient's condition must be confirmed, and it must also be taken into account that beta-blockers may be taken for other indications such as high blood pressure or arrhythmias.

Therefore, the need for beta-blockers in post-AMI patients with preserved ejection fraction must be assessed with a medical specialist.